InMed Pharmaceuticals (INM) Projected to Post Earnings on Tuesday

InMed Pharmaceuticals (NASDAQ:INM) is projected to post its Q3 2026 results before the market opens on Tuesday, May 12th. Analysts expect the company to announce earnings of ($94.4436) per share and revenue of $1.2010 million for the quarter. Parties may review the information on the company’s upcoming Q3 2026 earning report for the latest details on the call scheduled for Tuesday, May 12, 2026 at 4:00 PM ET.

InMed Pharmaceuticals (NASDAQ:INM) last released its quarterly earnings results on Thursday, February 12th. The company reported ($0.51) earnings per share (EPS) for the quarter. The firm had revenue of $0.82 million during the quarter. InMed Pharmaceuticals had a negative net margin of 170.08% and a negative return on equity of 73.63%.

InMed Pharmaceuticals Stock Performance

INM traded up $0.00 during trading on Tuesday, hitting $0.75. The stock had a trading volume of 6,016 shares, compared to its average volume of 95,075. The company has a 50 day moving average price of $0.76 and a 200-day moving average price of $1.14. The firm has a market cap of $2.49 million, a price-to-earnings ratio of -0.26 and a beta of 0.57. InMed Pharmaceuticals has a one year low of $0.58 and a one year high of $7.98. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.94 and a quick ratio of 5.30.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of InMed Pharmaceuticals in a research note on Tuesday, April 21st. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company has a consensus rating of “Sell”.

Hedge Funds Weigh In On InMed Pharmaceuticals

An institutional investor recently bought a new position in InMed Pharmaceuticals stock. Virtu Financial LLC acquired a new position in shares of InMed Pharmaceuticals Inc. (NASDAQ:INM) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 20,369 shares of the company’s stock, valued at approximately $45,000. Virtu Financial LLC owned about 0.73% of InMed Pharmaceuticals as of its most recent SEC filing. 20.12% of the stock is currently owned by institutional investors and hedge funds.

InMed Pharmaceuticals Company Profile

InMed Pharmaceuticals is a clinical-stage biopharmaceutical company headquartered in Vancouver, British Columbia, that is dedicated to the discovery and development of novel therapeutics derived from cannabinoids. Leveraging a proprietary drug discovery engine, the company works to identify, design and optimize cannabinoid-based molecules with the goal of addressing diseases that have significant unmet medical needs. InMed’s integrated business model combines research, development and manufacturing capabilities under one roof to streamline the progression of promising assets from preclinical studies into human trials.

The company’s pipeline features multiple lead programs targeting both neurological and dermatological disorders.